Needham & Company maintains a 'Hold' on Watson Pharmaceuticals (WPI); Generic Business Strength Allows 2Q11 Results to “Beat” Expectations
Tweet Send to a Friend
Needham & Company maintains a 'Hold' on Watson Pharmaceuticals (NYSE: WPI).
Needham analyst says, "WPI’s 2Q11 results, despite benefiting from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "WPI’s 2Q11 results, despite benefiting from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
